A study of lanreotide for neuroendocrine tumours of the pancreas or small bowel that have spread (PRODIGE 31, REMINET)

The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you. 

You may be able to join this study if all of the following apply.

• You have a single or several neuroendocrine tumours (NET) that started in the pancreas or small bowel (duodenum ) and have grown into surrounding tissues (locally advanced) or spread elsewhere in the body
• You have a NET that doesn’t produce extra hormones or a type of tumour called a gastrinoma
• A specialist doctor called a pathologist has looked at a sample of your tumour that was removed when you had a biopsy
• You have a slow growing tumour (the tumour is low to medium grade)
• You have had treatment because:
   
  • the tumour started causing symptoms, grew into more than half of the liver or spread to the bone and this is your first treatment
  • the tumour has grown before this treatment or after a previous treatment with somatostatin analogues such as lanreotide​

• The first treatment you had included chemotherapy for 3 to 6 months or a biological therapy  such as everolimus or sunitinib for 6 months
• Your tumour stayed the same size or shrunk after the first treatment and this was within 4 weeks of joining the study
• You have satisfactory blood test results
• You are well enough to be up and about for at least half the day (performance status 0,1 or 2)
• You are willing to use reliable contraception during treatment and for up to 6 months afterwards if you are a women and for 3 months afterwards if you are a man -  if there is any chance you or your partner could become pregnant
• You are at least 18 years old

You cannot join this study if any of these apply.

• The neuroendocrine cells look very abnormal under the microscope (they are poorly differentiated cells) or you have a fast growing (high grade) tumour 
• The area where the tumour started (the primary tumour) has been completely removed and the tumour areas remaining are just in the bone
• You have a family history of neuroendocrine tumours – for example you have a condition called MEN1
• You have diabetes that is not well controlled with medication
• You have had any other cancer in the last 5 years apart from non melanoma skin cancer  or early stage cancer of the cervix (CIS) that was successfully treated
• You are taking part in another trial of an experimental drug or have taken part in a trial within 30 days of starting study treatment
• You can’t have treatment with the study drug or you are allergic to it or anything it contains
• You are pregnant or breastfeeding